Please wait a minute...
European Journal of Gynaecological Oncology  2021, Vol. 42 Issue (1): 96-104    DOI: 10.31083/j.ejgo.2021.01.2265
Original Research Previous articles | Next articles
Pegylated-interferon-alpha treatment modifying T cell cytokine profile in tumor microenvironment of patients with cervical intraepithelial neoplasia
Fabiano Vilela Mundim1, Marco Aurélio Trovó2, Letícia Montes Stark3, Millena Prata Jammal4, Márcia Antoniazi Michelin1, Eddie Fernando Candido Murta4, *()
1Research Institute of Oncology (IPON)/Discipline of Immunology-Federal University of Triângulo Mineiro (UFTM), Uberaba, 38064200 MG, Brazil
2Department of Gynecology and Obstetrics-Federal University of Triângulo Mineiro (UFTM), Uberaba, 38.025-440 MG, Brazil
3Research Institute of Oncology (IPON)-Federal University of Triângulo Mineiro (UFTM), Uberaba, 38.025-440 MG, Brazil
4Research Institute of Oncology (IPON)/Department of Gynecology and Obstetrics-Federal University of Triângulo Mineiro (UFTM), Uberaba, 38064200 MG, Brazil
Download:  PDF(5336KB)  ( 90 ) Full text   ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: The goal of the investigation was to compare the profiles the cytokines IL-2, IL-12, IFN-γ, TNF-α, TGF-β, IL-4, IL-6 in the endocervical and serum secretions of patients with cervical intraepithelial neoplasia (CIN) who had good or poor response to immunotherapy with pegylated (PEG)-Interferon-alpha. Methods: The study was performed with 16 patients who had been diagnosed with CIN II and III. Each patient was submitted to six injections of PEG-Interferon-α-2b subcutaneously. After each injection, endocervical secretion and serum samples were collected for cytokine levels by ELISA. Results: Of the 16 women, 43.75% (n = 7) showed good clinical response and lesion regression after treatment as seen by histopathological analysis. When we analyzed the pre-therapy, locally we observed a higher concentration of IL-4 in patients who did not respond to treatment (P = 0.0229). After treatment, there was a significant reduction in IL-4 in unresponsive patients (P = 0.0304). Patients responsive to IFN-α had a reduction in the concentrations the TNF-α after treatment (P = 0.0313). Conclusion: Immunotherapy with PEG-Interferon-α can reduce the damage caused by HPV by decreasing local inflammation by reducing the cytokines IL-4 and TNF-alpha during treatment in endocervical secretion. It seems that the regression is related to the immunological profile, mainly local, before treatment, as in the case of IL-4 and TNF-alpha, promoting a Th2 profile in those patients with therapeutic failure.
Key words:  Cytokines      Immunotherapy      Cervical intraepithelial neoplasia     
Submitted:  06 October 2020      Revised:  09 December 2020      Accepted:  12 December 2020      Published:  15 February 2021     
Fund: 
Research Foundation Support of the State of Minas Gerais (FAPEMIG)
National Council for Scientific and Technological Development (CNPq)
*Corresponding Author(s):  Eddie Fernando Candido Murta     E-mail:  eddiemurta@mednet.com.br

Cite this article: 

Fabiano Vilela Mundim, Marco Aurélio Trovó, Letícia Montes Stark, Millena Prata Jammal, Márcia Antoniazi Michelin, Eddie Fernando Candido Murta. Pegylated-interferon-alpha treatment modifying T cell cytokine profile in tumor microenvironment of patients with cervical intraepithelial neoplasia. European Journal of Gynaecological Oncology, 2021, 42(1): 96-104.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.01.2265     OR     https://ejgo.imrpress.com/EN/Y2021/V42/I1/96

[1] Hye-yon Cho, Soobin Yim, Inji Yeo, Min Sun Kyung. The prevalence of abnormal pap smear in women with pelvic inflammatory disease and determine the risk factors of cervical intra-epithelial neoplasia 2/3[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 105-109.
[2] Kaori Hoshino, Yasuyuki Kinjo, Hiroshi Harada, Taeko Ueda, Yoko Aoyama, Midori Murakami, Seiji Kagami, Yusuke Matsuura, Kiyoshi Yoshino. Outcomes and complications of total laparoscopic hysterectomy after conization[J]. European Journal of Gynaecological Oncology, 2021, 42(1): 122-128.
[3] Ha Na Yun, Woo Dae Kang, U Chul Ju, Seok Mo Kim. Human papillomavirus genotyping is a reliable prognostic marker of recurrence for high-grade cervical intraepithelial neoplasia (CIN2-3) with positive margins after loop electrosurgical excision procedure[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 969-974.
[4] Behiye Pinar Goksedef, Burak Giray, Canan Kabaca, Murat Ekmez, Sinan Gulec, Esra Keles, Isa Aykut Ozdemir, Suleyman Salman, Derya Sivri Aydin. Utility of colposcopy in the management of ASCUS and LSIL in women younger than 25-year-old: A retrospective multicenter study[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 685-688.
[5] Panteleimon Mnimatidis, Abraham Pouliakis, George Valasoulis, George Michail, Aris Spathis, Christine Cottaridi, Niki Margari, Maria Kyrgiou, Maria Nasioutziki, Alexandros Daponte, Konstantinos Dinas, Evangelos Paraskevaidis, Ioannis Panayiotides, Dimitrios-Dionysios Koutsouris. Multicentric assessment of cervical HPV infection co-factors in a large cohort of Greek women[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 545-555.
[6] A.K. Fischer, K. Reuter-Jessen, H.-U. Schildhaus, T. Hugo, A.H. Scheel, S. Merkelbach-Bruse, E. Heinmöller, R. Buettner, B. Jasani, J. Walbeck, J.Rüschoff, P. Middel. Development of high-risk HPV associated cervical dysplasia despite HPV-vaccination: a regional dysplasia center cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 80-84.
[7] J.-H. Kim, D.-Y. Kim. Imiquimod as an alternative option for young women with high-grade cervical intraepithelial neoplasia[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 943-947.
[8] E. Palma, M. Bertini. Vaginal microbiota and the pathobiosis path: its role in the evolution of HPV cervical intraepithelial neoplasia and cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 534-537.
[9] P. Ortega-Quiñonero, M. Remezal-Solano, M.C. Carazo-Díaz, D. Prieto-Merino, M.I. Urbano-Reyes, L. García de Guadiana-Romualdo, J.P. Martínez-Cendán. Impact of the human papillomavirus vaccination on patients who underwent conization for high-grade cervical intraepithelial neoplasia[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 402-407.
[10] F. Liu, D.H. Hu, M.J. Fei, Y.F. Zhang, B. Wang, C.Y. Wang, K. Huang. Evaluation of p16/Ki67 dual staining compared with high-risk HPV testing to assess liquid-based cytology with atypical squamous cells of unknown significance[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 249-253.
[11] Aiping Fan, Chen Wang, Liqin Zhang, Ye Yan, Yingmei Wang, Cha Han, Fengxia Xue. The effect of different cervical transformation zone types on the colposcopic diagnosis of cervical intraepithelial neoplasia[J]. European Journal of Gynaecological Oncology, 2019, 40(2): 290-294.
[12] Hsiu-Huei Peng, Yi-Lun Wang, Cheng-Tao Lin. Concurrent chemoradiotherapy combined with immunotherapy is superior to traditional concurrent chemoradiotherapy in the treatment of advanced cervical cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(1): 36-39.
[13] A. Abe, M. Nishimura, M. Irahara. "See and treat" LEEP biopsy for cervical intraepithelial neoplasia grade 2/3[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 958-962.
[14] Yujie Chen, Jing Chen, Lan Yang, Yanming Jiang, Li Li, Wenjuan Yi, Lifang Lan, Liuhong Zhang. Lower genital tract infection and other factors associated with cervial intraepithelial neoplasia: a hospital-base case-control study[J]. European Journal of Gynaecological Oncology, 2018, 39(5): 795-799.
[15] M.T. Schettino, G. Mainini, F.P. Ammaturo, P. De Franciscis, M. Torella, F. Grauso, E.M. Messalli, G. Balbi, M.F. Offi, N. Colacurci. The role of human papillomavirus in cervical pre-neoplastic lesions: the relationship between virus genotype and persistence or clearance of the infection[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 564-568.
No Suggested Reading articles found!